June 28, 2023 – Medline announced that after more than 26 years of leadership, Charlie Mills (CEO), Andy Mills (President) and Jim Abrams (COO) will retire from their current roles. They will continue to serve the company on its Board of Directors, with Charlie Mills leading as Chairman of the Board and Andy Mills and Jim Abrams as Vice Chairmen. To culminate a five-year succession planning process, Medline has elevated company executives Jim Boyle to serve as the next Chief Executive Officer, and Jim Pigott as the next President & Chief Operating Officer. The leadership transition will be effective October 1, 2023.
“Jim Boyle and Jim Pigott have been instrumental in Medline’s growth and success during their nearly 60 years combined within the organization, and we are excited for them to lead us into the future,” said Charlie Mills, current chief executive officer of Medline. “In blending Medline’s high-performance culture and customer-centric approach with their extensive understanding of healthcare, they are perfectly suited to propel Medline forward while continuing to build upon our rich legacy.”
Boyle joined Medline in 1996 and has served as Executive Vice President since 2018, managing its customer base of over 5,000 healthcare providers across the continuum of care and overseeing more than $21 billion of annual sales. Boyle was responsible for the strategic direction and execution of the commercial functions across all healthcare segments, as well as the Marketing, Operations and Logistics departments. In addition, he oversaw Medline’s distributed products business and led the customer support infrastructure, meeting the unique challenges of Medline’s customer base and its patient communities.
Pigott joined Medline in 1992 and most recently served as Executive Vice President. In this role, he oversaw the strategy and execution of Medline’s 27 product divisions, comprised of more than 20 manufacturing sites and 14,000 employees. In addition, Pigott led Medline’s global sourcing and inventory management organizations. Over the years, he was involved in the company’s expansion into several product segments, including surgical, laboratory, diagnostics and cardiology, as well as the growth of its domestic manufacturing footprint.